Monitor whether the company satisfies the $15M prepayment condition by November 30, 2026 to keep the Perceptive Sixth Amendment in effect. The offering's size and pricing will determine dilution magnitude; watch for the final prospectus supplement with filled-in terms.
Drugs in focus
STIM drug pipeline →NeuroStar
● Neutral Named in this 424B5- Impact
- Phase
- Approved / Commercialized
- Time to market
- Already commercialized. NeuroStar has been FDA-cleared and marketed since 2008 for adult MDD, with additional indications (OCD, adolescent MDD, anxious depression) added through subsequent 510(k) clearances, most recently in March 2024.
- Next catalyst
- None dated
What to watchThe next catalyst for STIM is the Q4 2026 earnings report, expected in early February 2027, which will show whether the company can sustain its return to operating profitability and positive adjusted EBITDA. The integration of the TrakStar platform with AdvancedMD (scheduled for Q4 2026) and any updates on the Greenbrook clinic expansion and COMP360 collaboration readiness are also worth watching. There is no binary FDA decision or pivotal readout on the horizon since NeuroStar is already fully commercialized.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $1.62entry
- T+1 · 5d ago −11.73%α −11.37% · $1.43
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neuronetics filed a 424B5 prospectus supplement for an underwritten public offering of common stock, with share count, price, and net proceeds left as placeholders (TBD). Proceeds will partially repay the $65M Perceptive credit facility (11.5% interest) and fund general corporate purposes. The offering follows a Q3 2026 earnings beat (revenue $42.0M, +12.5% YoY; EPS -$0.02 vs -$0.11 consensus) and a November 5, 2026 amendment to the Perceptive Facility that requires a $15M prepayment by November 30, 2026 to avoid automatic termination. The company has a going concern warning tied to trailing twelve-month revenue projections.
Key Financial Metrics
Key Facts
- Underwritten public offering of common stock (share count TBD) with 30-day underwriter option for additional shares
- Last reported sale price on November 9, 2026 was $2.18 per share
- Net proceeds will partially repay the $65M Perceptive Facility (11.5% interest, matures July 2029)
- Perceptive Sixth Amendment (Nov 5, 2026) requires a $15M prepayment by Nov 30, 2026 or it terminates
- Company has a going concern warning based on trailing twelve-month revenue projections
- 77,728,311 shares outstanding as of September 30, 2026; net tangible book value was $(18.3)M or $(0.24) per share
- Underwriters: William Blair (lead), BTIG, Canaccord Genuity; 90-day lock-up for company, 90/30-day for insiders/stockholders
- Directors and related parties have indicated interest in purchasing shares at the public offering price
Financial Impact
Offering size TBD; proceeds will repay a portion of $65M Perceptive Facility debt at 11.5% interest; net tangible book value was negative $(18.3)M as of Sep 30, 2026
Risk Factors
- Going concern risk: trailing twelve-month revenue may fall below amended covenant minimums
- Perceptive Sixth Amendment automatically terminates if $15M prepayment condition not met by Nov 30, 2026
- Immediate and substantial dilution to existing shareholders from the offering
- Stock price volatility; company has a history of Nasdaq minimum bid price non-compliance
- High debt load ($65M at 11.5%) and restrictive covenants limit financial flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-455694 |
| Document: 0001193125-26-455694-index-headers.html | 0001193125-26-455694 |
| Document: 0001193125-26-455694-index.html | 0001193125-26-455694 |
| Document: 0001193125-26-455694.txt | 0001193125-26-455694 |
Track record
30 reports on STIM
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +11.73% at T+1 after the Nov 10, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13D/A Neutral 4/10 Entry price pending
- Nov 16, 2026today SC 13D/A Bearish 6/10 Entry price pending
- Nov 12, 20264d ago 8-K/A Bearish 5/10 Entry $1.39 to $1.25 Now $1.25 +10.07% ▲ +10.07% +8.16% vs SPY
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $1.43 to $1.39 Now $1.25 +12.59% ▲ +2.80% +2.43% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.43 to $1.39 Now $1.25 +12.59% ▲ +2.80% +2.43% vs SPY
- Nov 10, 20265d ago Press Release Bearish 6/10 Entry $1.62 to $1.43 Now $1.25 +22.84% ▲ +11.73% +11.37% vs SPY
- Nov 10, 20266d ago 424B5 Bearish 6/10 Viewing Entry $1.62 to $1.43 Now $1.25 +22.84% ▲ +11.73% +11.37% vs SPY
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.62 to $1.43 Now $1.25 −22.84% ▼ −11.73% −11.37% vs SPY
- Nov 10, 20266d ago Press Release Bearish 6/10 Entry $1.62 to $1.43 Now $1.25 +22.84% ▲ +11.73% +11.37% vs SPY
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $2.01 to $1.62 Now $1.25 −37.81% ▼ −19.40% −20.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers